Community Heart and Vascular Hospital (CHVH) announced Community Physician Network (CPN) electrophysiologist, Emily Rose, MD, is the first in Central Indiana and among the first in the nation to implant a single-chamber implantable cardiac device (ICD) developed by BIOTRONIK, a leading manufacturer of cardiovascular medical technology.
Last month the Food and Drug Administration (FDA) granted final approval for the
BIOTRONIK Lumax 740 DX System. The device is a first-in-class ICD that utilizes a single lead with atrial sensing capabilities. Single-chamber ICDs are sophisticated electronic devices that employ a thin flexible wire, known as a lead, to deliver an electrical shock to the heart when the heart rate becomes dangerously fast.
For patients who have, or are at risk of developing atrial fibrillation (A-fib), a physician may
consider implanting a dual-chamber ICD, which utilizes two leads and has pacemaker functions built in. Implanting multiple leads in the heart has been shown to increase the risk of complications, and the use of dual-chamber devices in patients without a clear indication for the additional atrial lead has received a great deal of attention in recent months. The new single lead ICD can detect dangerous heart rhythms in both the lower chamber, or ventricle and the upper chamber, or atrium.
“The DX System was constructed with the patient in mind. While expanding on the benefits of single-chamber ICDs, the new technology provides us with atrial sensing capabilities and home monitoring to keep an eye on important atrial conditions such as A-fib,” stated Rose, MD.
The BIOTRONIK Lumax 740 DX Systemalso integrates with BIOTRONIK Home Monitoring®, allowing physicians to remotely follow their DX patients’ clinical and device statuses daily—at anytime, anywhere in the world. The cellular-based platform has the ability to detect clinically relevant events, including silent, asymptomatic arrhythmias, and device related issues, allowing for earlier medical intervention.